Arcturus Therapeutics LTD. – Ordinary Shares (NASDAQ:ARCT) Sellers Covered 8.66% of Their Shorts

September 16, 2018 - By Carolyn Hewitt

The stock of Arcturus Therapeutics LTD. – Ordinary Shares (NASDAQ:ARCT) registered a decrease of 8.66% in short interest. ARCT’s total short interest was 112,900 shares in September as published by FINRA. Its down 8.66% from 123,600 shares, reported previously. With 18,800 shares average volume, it will take short sellers 6 days to cover their ARCT’s short positions. The short interest to Arcturus Therapeutics LTD. – Ordinary Shares’s float is 1.73%.

The stock increased 6.64% or $0.56 during the last trading session, reaching $9. About 13,808 shares traded. Arcturus Therapeutics Ltd. (NASDAQ:ARCT) has risen 4.38% since September 16, 2017 and is uptrending. It has underperformed by 11.24% the S&P500.

Arcturus Therapeutics Ltd. operates as an RNA medicines company. The company has market cap of $96.70 million. The Company’s RNA therapeutics platforms could be applied in various types of RNA medicines, including small interfering RNA, messenger RNA, replicon RNA, antisense RNA, microRNA, and gene editing therapeutics. It currently has negative earnings. The firm owns LUNAR lipid-mediated delivery and Unlocked Nucleomonomer Agent technology, including UNA Oligomers, which are covered by its patent portfolio, including 120 patents and patent applications issued in the United States, Europe, Japan, China, and other countries.

More news for Arcturus Therapeutics Ltd. (NASDAQ:ARCT) were recently published by: Nasdaq.com, which released: “Arcturus Therapeutics Announces Appointment of Ernst & Young LLP as the Company’s Independent Auditor” on August 29, 2018. Globenewswire.com‘s article titled: “Arcturus Therapeutics Appoints Andrew Sassine as Interim Chief Financial Officer” and published on August 28, 2018 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.